{"id":"https://openalex.org/W2123484049","doi":null,"title":"Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.","display_name":"Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.","alternate_titles":[],"publication_year":2001,"publication_date":"2001-07-01","ids":{"openalex":"https://openalex.org/W2123484049","mag":"2123484049","pmid":"https://pubmed.ncbi.nlm.nih.gov/11408362"},"language":"en","primary_location":{"id":"pmid:11408362","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11408362","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug metabolism and disposition: the biological fate of chemicals","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W2123484049"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058873524","display_name":"Thomas Kerbusch","orcid":"https://orcid.org/0000-0003-4564-5614","observed_orcids":["https://orcid.org/0000-0003-4564-5614"]},"institutions":[{"id":"https://openalex.org/I2802065108","display_name":"Slotervaartziekenhuis","ror":"https://ror.org/01w502745","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802065108"]},{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T Kerbusch","raw_affiliation_strings":["Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands. thomas.kerbusch@biof.uu.se"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands. thomas.kerbusch@biof.uu.se","institution_ids":["https://openalex.org/I2802065108","https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021986417","display_name":"Ron A. A. Math\u00f4t","orcid":"https://orcid.org/0000-0001-8401-0879","observed_orcids":["https://orcid.org/0000-0001-8401-0879"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R A Math\u00f4t","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109220316","display_name":"H.J. Keizer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H J Keizer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038232681","display_name":"G.P. Kaijser","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G P Kaijser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000418012","display_name":"Jan H.M. Schellens","orcid":"https://orcid.org/0000-0001-6832-1976","observed_orcids":["https://orcid.org/0000-0001-6832-1976"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J H Schellens","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5062227574","display_name":"Jos H. Beijnen","orcid":"https://orcid.org/0000-0003-0118-561X","observed_orcids":["https://orcid.org/0000-0003-0118-561X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J H Beijnen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3502,"has_fulltext":false,"cited_by_count":42,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.519844,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"29","issue":"7","first_page":"967","last_page":"975"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9258000254631042,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9258000254631042,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.026900000870227814,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.01269999984651804,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ifosfamide","display_name":"ifosfamide","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9210000038146973},{"id":"https://openalex.org/keywords/infusion-time","display_name":"infusion duration","score":0.9409999847412109},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6980000138282776},{"id":"https://openalex.org/keywords/autoinduction","display_name":"autoinduction","score":0.9229999780654907},{"id":"https://openalex.org/keywords/prodrug-activation","display_name":"prodrug activation","score":0.6710000038146973},{"id":"https://openalex.org/keywords/population-pharmacokinetic-model","display_name":"population pharmacokinetic model","score":0.6579999923706055},{"id":"https://openalex.org/keywords/inter-individual-variability","display_name":"interindividual variability","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2777506904","wikidata":"https://www.wikidata.org/wiki/Q418560","display_name":"Ifosfamide","level":4,"score":0.9888763427734375},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8839438557624817},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.8214422464370728},{"id":"https://openalex.org/C2778670039","wikidata":"https://www.wikidata.org/wiki/Q414004","display_name":"Nitrogen mustard","level":4,"score":0.7159864902496338},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6875373721122742},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.5855844616889954},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.5732461214065552},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.500636100769043},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.41891908645629883},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3693828582763672},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3024928867816925},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18137797713279724},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.1590059995651245},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1428966224193573},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.14113545417785645}],"mesh":[{"descriptor_ui":"D001499","descriptor_name":"Bayes Theorem","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002849","descriptor_name":"Chromatography, Gas","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007069","descriptor_name":"Ifosfamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007069","descriptor_name":"Ifosfamide","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"pmid:11408362","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11408362","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug metabolism and disposition: the biological fate of chemicals","raw_type":"Journal Article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/ec0352cf-9df3-4653-9c9d-2fb95002ab1d","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/ec0352cf-9df3-4653-9c9d-2fb95002ab1d","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kerbusch, T, Math\u00f4t, R A, Keizer, H J, Kaijser, G P, Schellens, J H & Beijnen, J H 2001, 'Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites', Drug metabolism and disposition: the biological fate of chemicals, vol. 29, no. 7, pp. 967-975.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/2bffd985-9d38-40f4-ac53-9089590ed3bb","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/influence-of-dose-and-infusion-duration-on-pharmacokinetics-of-ifosfamide-and-metabolites(2bffd985-9d38-40f4-ac53-9089590ed3bb).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drug metabolism and disposition: the biological fate of chemicals, 29(7), 967 - 975. American Society for Pharmacology and Experimental Therapeutics","raw_type":"info:eu-repo/semantics/article"},{"id":"mag:2123484049","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11408362","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W185249808","https://openalex.org/W1504223539","https://openalex.org/W1511387305","https://openalex.org/W1858095914","https://openalex.org/W1866616545","https://openalex.org/W1967153032","https://openalex.org/W1983529502","https://openalex.org/W1990343665","https://openalex.org/W1995081817","https://openalex.org/W1996473646","https://openalex.org/W2001352576","https://openalex.org/W2003669623","https://openalex.org/W2014298542","https://openalex.org/W2015922250","https://openalex.org/W2047664336","https://openalex.org/W2151863911","https://openalex.org/W2336704086","https://openalex.org/W2399843955","https://openalex.org/W2404156817"],"related_works":["https://openalex.org/W2154329849","https://openalex.org/W2244468434","https://openalex.org/W2146656684","https://openalex.org/W2145175703","https://openalex.org/W2399843955","https://openalex.org/W1966040161","https://openalex.org/W2029478462","https://openalex.org/W1967153032","https://openalex.org/W2061438971","https://openalex.org/W7220680337"],"abstract_inverted_index":{"The":[0,32,90,111,231],"anticancer":[1],"drug":[2],"ifosfamide":[3,19,82,99,157,172,185,201,219,245],"is":[4],"a":[5,147],"prodrug":[6],"requiring":[7],"activation":[8],"through":[9],"4-hydroxyifosfamide":[10],"to":[11,14,21,38,41,76,103,139,200,224],"ifosforamide":[12,52],"mustard,":[13],"exert":[15],"cytotoxicity.":[16],"Deactivation":[17],"of":[18,28,34,45,67,81,95,98,141,218],"leads":[20],"2-":[22,47],"and":[23,25,40,48,51,61,83,135,162,186,202,208,227,234],"3-dechloroethylifosfamide":[24,189],"the":[26,43,78,96,108,153,156,216,222,225],"release":[27],"potentially":[29],"neurotoxic":[30],"chloracetaldehyde.":[31],"aim":[33],"this":[35],"study":[36,213],"was":[37,74,101,113],"quantify":[39],"compare":[42],"pharmacokinetics":[44,80],"ifosfamide,":[46],"3-dechloroethylifosfamide,":[49],"4-hydroxyifosfamide,":[50],"mustard":[53],"in":[54,87,152,167,197],"short":[55,122,192,207],"(1-4":[56],"h),":[57,60],"medium":[58,209],"(24-72":[59],"long":[62,117,175],"infusion":[63,109,118,123,176,193,210,220,235],"durations":[64,119,177],"(96-240":[65],"h)":[66],"ifosfamide.":[68],"An":[69],"integrated":[70],"population":[71],"pharmacokinetic":[72],"model":[73],"used":[75],"describe":[77],"autoinducible":[79],"its":[84,131,228],"four":[85],"metabolites":[86,203],"56":[88],"patients.":[89],"rate":[91,112],"by":[92],"which":[93],"autoinduction":[94],"metabolism":[97],"developed":[100],"found":[102],"be":[104,140,239],"significantly":[105,182],"dependent":[106],"on":[107],"schedule.":[110],"52%":[114],"lower":[115],"with":[116,121,130,170,191],"compared":[120,190],"durations.":[124,194,211],"This":[125,212],"difference":[126],"was,":[127,136],"however,":[128],"comparable":[129],"interindividual":[132],"variability":[133],"(22%)":[134],"therefore,":[137],"considered":[138],"minor":[142],"clinical":[143],"importance.":[144],"Autoinduction":[145],"caused":[146],"less":[148],"than":[149,164],"proportional":[150,165],"increase":[151,166],"area":[154],"under":[155],"plasma":[158],"concentration-time":[159],"curve":[160],"(AUC)":[161],"more":[163],"metabolite":[168,229],"exposure":[169,199,223],"increasing":[171],"dose.":[173],"During":[174],"dose-corrected":[178],"exposures":[179],"(AUC/D)":[180],"were":[181,204],"decreased":[183],"for":[184,188],"increased":[187],"No":[195],"differences":[196],"dose-normalized":[198],"observed":[205,232],"between":[206],"demonstrates":[214],"that":[215],"duration":[217,236],"influences":[221],"parent":[226],"3-dechloroethylifosfamide.":[230],"dose":[233],"dependence":[237],"should":[238],"taken":[240],"into":[241],"account":[242],"when":[243],"modeling":[244],"metabolism.":[246]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2123484049","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
